COMMUNIQUÉS West-GlobeNewswire

Lifeward Expands International Distribution of its ReWalk® Personal Robotic Exoskeleton into Mexico, Thailand, and the United Arab Emirates
17/12/2025
Distribution agreement with Singapore-based Verita Neuro will provide patients the ReWalk Personal Exoskeleton as part of its multi-layered treatment modalities New delivery model for ReWalk will integrate in-patient [...]
Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
17/12/2025
Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine Company on track to conduct formal interim analysis [...]
VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement
17/12/2025
Following closing, combined company plans to progress Yarrow’s lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor (“TSHR”) antibody for Graves’ disease (“GD”) and thyroid eye [...]
TadHealth Awarded San Diego County Office of Education Contract; School Districts to Begin CYBHI Billing in January 2026
17/12/2025
COSTA MESA, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- TadHealth , a leading provider of school-based mental health technology, has been selected by the San Diego County Office of Education (SDCOE) to deliver a county- [...]
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
17/12/2025
Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed healthy volunteers Study results support the chronic dosing of SAB-142 in an [...]
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
17/12/2025
SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, [...]
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors
17/12/2025
Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta Results demonstrated WP1066 induces anti-tumor immune responses and were [...]
Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial
17/12/2025
First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 Trial Builds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s Patients Treated with Anti-Amyloid Therapies BOSTON [...]
Alira Health Appoints Dr. Susanne Schaffert as Senior Advisor and Patient-Centric Ambassador
17/12/2025
FRAMINGHAM, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Alira Health, a global advisory firm and CRO, today announced the appointment of Dr. Susanne Schaffert as Senior Advisor and Patient-Centric Ambassador. Dr. Schaffert [...]
Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026
17/12/2025
PONTE VEDRA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation [...]
INVO Fertility Signs Definitive Purchase Agreement to Acquire Indiana-Based Fertility Clinic “Family Beginnings”
17/12/2025
Signing of definitive purchase agreement represents critical next step in completing previously announced acquisition SARASOTA, Fla. and INDIANAPOLIS, Dec. 17, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF [...]
Vaso Corporation Announces Fifth Extension of Sales Representation Agreement with GE HealthCare
17/12/2025
Vaso Corporation 137 Commercial Street Plainview, New York 11803 Tel: (516) 997-4600 Fax: (516) 997-2299 Investor Contact: Jonathan Newton Investor Relations Phone: 516-997-4600 Email: jnewton@vasocorporation.com [...]
Incyclix Bio Expands Board of Directors with Appointment of Dr. Kimberly Blackwell
17/12/2025
RESEARCH TRIANGLE PARK, N.C., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of [...]
Population Health Partners and dacadoo Announce Strategic Partnership to Advance Digital Health Engagement and Outcome-Based Healthcare
17/12/2025
New York and Zurich, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Population Health Partners , L.P., a global investor in people and technologies that generate health span and superior returns, and dacadoo , a global leader in [...]
Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy
17/12/2025
The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to female patients with sexual dysfunction in order to increase sexual quality of [...]
SafeSpace Global Corporation (OTCID: SSGC) Appoints Harvest Communications as Investor Relations and Corporate Communications Consulting Agency
17/12/2025
Knoxville, TN, Dec. 17, 2025 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (OTCID: SSGC), an AI technology company dedicated to protecting lives across education, healthcare, transportation, and correctional [...]
Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point
17/12/2025
Completion of Enrollment Positions CELZ for Near-Term Data Catalysts and Accelerates Path Toward Commercialization of a Transformative, Non-Opioid Therapy for Chronic Lower Back Pain PHOENIX, Dec. 17, 2025 (GLOBE [...]
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment
17/12/2025
Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study LEVEL On Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half of 2026 Global Phase 3 [...]
Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock
17/12/2025
EMERYVILLE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune [...]

Pages